secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084309
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia FDA lifts clinical hold on nex-z MAGNITUDE Phase 3 trial for ATTR-CM
-----------------------------------------------------------------------------

- FDA removed clinical hold on MAGNITUDE Phase 3 trial of nex-z for ATTR-CM after Grade 4 liver event on Oct 29, 2025.
- Mitigation measures include enhanced liver monitoring, short-term steroid guidance, and exclusion of certain liver abnormalities.
- For MAGNITUDE, added exclusion criteria for recent cardiovascular instability and ejection fraction <25%.
- MAGNITUDE-2 clinical hold for ATTRv-PN was resolved in January 2026; enrollment activities resuming.
- Amended ATM offering to up to $1.035B aggregate (from $750M); $635M sold, up to $400M additional shares remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/0001193125-26-084309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/d101756d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer